Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 18:16:241-248.
doi: 10.2147/VHRM.S230639. eCollection 2020.

The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy

Meisam Saberi  1 , Zahra Ramazani  1 , Homeira Rashidi  2 , Alihossein Saberi  3
Affiliations

The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy

Meisam Saberi et al. Vasc Health Risk Manag. .

Abstract

Aim: Type 2 diabetes (T2D), as a major cause of morbidity and mortality, is predicted to have a prevalence of 629 million by 2045. As diabetic patients show considerable inter-individual variation in response to antidiabetic treatment, this study aimed to investigate the gene polymorphism of cytochrome P450 as well as the effectiveness and safety of glibenclamide and gliclazide for different genotypes of CYP2C9. Besides, the chronic side effects of T2D including retinal microvasculature complications or retinopathy and renal dysfunction due to nephropathy in different genotypes were considered.

Patients and methods: The participants including 80 T2D patients treated with glibenclamide or gliclazide were recruited from university hospitals of Ahvaz Jundishpur University of Medical Sciences, Ahvaz, in the southwest of Iran. Blood samples were collected from the patients at 2.5h after the morning dose of glibenclamide and 12h after the last dose of gliclazide. Genotyping from the extracted DNA was, then, performed using PCR-RFLP. The plasma level of glibenclamide and gliclazide was, in turn, measured by the reverse-phase high-pressure liquid chromatography.

Results: The results showed that the wild-type allele, i.e., CYP2C9*1, occurred in the highest frequency (0.8), while the frequency rates of the mutant allele, i.e., CYP2C9*2 and CYP2C9*3, were 0.15 and 0.05, respectively. Moreover, no significant association was found between any of the genotypes as well as the clinical and biochemical characteristics of the patients. The findings also showed that the plasma level of sulfonylureas (i.e., glibenclamide and gliclazide) was the highest in the patients with the CYP2C9*3 allele. It was also found that 75.9% of the patients with variant genotypes had experienced hypoglycemia events. Furthermore, in the absence of wild type allele, a significant increase was observed in retinopathy (p=0.039) and nephropathy (p=0.05).

Conclusion: The findings can provide guidelines for the optimal management of the treatment protocols with sulfonylurea intended to control the T2D complications.

Keywords: CYP2C9; glibenclamide; gliclazide; nephropathy; retinopathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Association of retinopathy and different genotypes of CYP2C9.
Figure 2
Figure 2
Association of nephropathy and different genotypes of CYP2C9.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Federation ID, editor. IDF Diabetes Atlas Update Poster. Brussels, Belgium: International Diabetes Federation; 20152015.
    1. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non—insulin-department diabetes mellitus. Arch Intern Med. 1997;157(8):836–848. doi:10.1001/archinte.1997.00440290014001 - DOI - PubMed
    1. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP IV. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268(5209):423. doi:10.1126/science.7716547 - DOI - PubMed
    1. Tessier D, Dawson K, Tetrault J, Bravo G, Meneilly G. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med. 1994;11(10):974–980. doi:10.1111/j.1464-5491.1994.tb00256.x - DOI - PubMed
    1. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17(6):467–473. doi:10.1002/dmrr.235 - DOI - PubMed

MeSH terms